Literature DB >> 2783837

Mitral leaflet billowing and prolapse: its prevalence around the world.

T O Cheng1, J B Barlow.   

Abstract

Primary mitral leaflet billowing, or so-called mitral valve prolapse, has become the most common valve anomaly in the United States and is also frequently found throughout the world. Its prevalence varies from less than 1% to 38%, differing not only between countries but also within the same country. The prevalence depends on whether the study is clinical or echocardiographic, based on autopsy or surgical material, or of hospital or non-care-seeking population. Other explanations for the varying prevalence are the age, sex and weight differences of the study population, imprecise terminology, the care with which auscultation and/or echocardiography are carried out and interpreted, and some selection biases. Although prevalent throughout the world, the condition is generally benign and can often be regarded as a normal variant. Among the complications of mitral valve prolapse, progressive mitral regurgitation and infective endocarditis are particularly noteworthy. Primary mitral valve prolapse is currently a leading cause of mitral regurgitation and also of infective endocarditis.

Entities:  

Mesh:

Year:  1989        PMID: 2783837     DOI: 10.1177/000331978904000201

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  3 in total

1.  Evaluation of mitral valve prolapse using newly developed real-time three-dimensional echocardiographic system with real-time volume rendering.

Authors:  Omer Goktekin; Makoto Matsumura; Ryozo Omoto; Shunei Kyo; Tsuyoshi Mochizuki
Journal:  Int J Cardiovasc Imaging       Date:  2003-02       Impact factor: 2.357

2.  Mitral valve prolapse--do all patients need an echocardiogram?

Authors:  M L Ong
Journal:  Postgrad Med J       Date:  1991-06       Impact factor: 2.401

3.  Mitral valve prolapse--from a normal variant to a pathologic entity.

Authors:  T O Cheng
Journal:  J Gen Intern Med       Date:  1988 Nov-Dec       Impact factor: 5.128

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.